MDM2 Suppresses p73 Function without Promoting p73 Degradation

REFERENCES

• Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and J. Kelly 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175–1184.
   PubMed Web of Science ®Google Scholar
• Barak, Y., T. Juven, R. Haffner, and J. Oren 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468.
   PubMed Web of Science ®Google Scholar
• Barak, Y., E. Gottlieb, T. Juven-Gershon, and J. Oren 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1739–1749.
   PubMed Web of Science ®Google Scholar
• Bian, J., and J. Sun 1997. P53CP, a putative p53 competing protein, that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc. Natl. Acad. Sci. USA. 94:14753–14758.
   PubMedGoogle Scholar
• Bottger, A., V. Bottger, A. Sparks, W. L. Liu, S. F. Howard, and J. Lane 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860–869.
   PubMed Web of Science ®Google Scholar
• Cahilly-Snyder, L., T. Yang-Feng, U. Francke, and J. George 1987. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet. 13:235–244.
   PubMedGoogle Scholar
• Chen, J., V. Marechal, and J. Levine 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107–4114.
   PubMed Web of Science ®Google Scholar
• Chen, J., J. Lin, and J. Levine 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:142–152.
   PubMedGoogle Scholar
• Chen, J., X. Wu, J. Lin, and J. Levine 1996. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445–2452.
   PubMed Web of Science ®Google Scholar
• Chen, L., S. Agrawal, W. Zhou, R. Zhang, and J. Chen 1998. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95:195–200.
   PubMedGoogle Scholar
• Cordon Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, M. F. Brennan, and J. Levine 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:794–799.
   PubMedGoogle Scholar
• Dulic, V., W. K. Kaufmann, S. J. Lees, T. D. Tisty, E. Lees, J. W. Harper, S. J. Elledge, and J. Reed 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and J. Vogelstein 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and J. Levine 1996. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:439–451.
   PubMed Web of Science ®Google Scholar
• Fakharzadeh, S. S., S. P. Trusko, and J. George 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–1569.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301–306.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., C. B. Epstein, J. C. Roth, and J. Levine 1997. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 3:248–259.
   PubMed Web of Science ®Google Scholar
• Gottlieb, T. M., and J. Oren 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta Gene Struct. Expression 1287:77–102.
   PubMed Web of Science ®Google Scholar
• Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. Xiao, S. Kumar, P. M. Howley, and J. Livingston 1998. P300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405–415.
   PubMed Web of Science ®Google Scholar
• Gu, W., X. L. Shi, and J. Roeder 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819–823.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., Y. Barak, and J. Oren 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596–1606.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and J. Oren 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Hermeking, H., C. Lengauer, K. Polyak, T. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and J. Vogelstein 1997. 14-3-3ς is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3–11.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and J. Yasuda 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. E. Roe, L. A. Donehower, and J. Bradley 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208.
   PubMed Web of Science ®Google Scholar
• Jost, C. A., D. Ginsberg, and J. Kaelin 1996. A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Virology 220:78–90.
   PubMedGoogle Scholar
• Jost, C. A., M. C. Marin, and J. Kaelin 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191–194.
   PubMed Web of Science ®Google Scholar
• Jost, C. A., and W. G. Kaelin. Unpublished data.
   Google Scholar
• Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. Biscan, A. Valent, A. Minty, P. Chalon, J. Lelias, X. Dumont, P. Ferrara, F. McKeon, and J. Caput 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819.
   PubMed Web of Science ®Google Scholar
• Ko, J. L., and J. Prives 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• Kovalev, S., N. Marchenko, S. Swendeman, M. LaQuaglia, and J. Moll 1998. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9:897–903.
   PubMedGoogle Scholar
• Kubbutat, M. H. G., S. N. Jones, and J. Vousden 1997. Regulation of p53 stability by mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and J. Vousden 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18:5690–5698.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and J. Livingston 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823–827.
   PubMed Web of Science ®Google Scholar
• Lin, J., J. Chen, B. Elenbass, and J. Levine 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to MDM2 and the adenovirus 5 E1B 55-kd protein. Genes Dev. 8:1235–1246.
   PubMed Web of Science ®Google Scholar
• Lozano, G., and J. de Montes 1998. MDM2 function. Biochim. Biophys. Acta Rev. Cancer 1377:M53–M57.
   Google Scholar
• Lu, H., and J. Levine 1995. Human TAF-31 is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92:5154–5158.
   PubMedGoogle Scholar
• Lu, H., J. Lin, J. Chen, and J. Levine 1996. Regulation of p53 transcriptional function: TAFs and MDM2. Harvey Lect. 90:81–93.
   Google Scholar
• Lu, H., Y. Taya, M. Ikeda, and J. Levine 1998. Phosphorylation of p53 at serine 389 is responsive uniquely to UV- but not to gamma- and etoposide-induced DNA damage. Proc. Natl. Acad. Sci. USA 95:6399–6402.
   PubMed Web of Science ®Google Scholar
• Marin, M. C., C. A. Jost, M. S. Irwin, J. A. DeCaprio, D. Caput, and J. Kaelin 1998. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18:6316–6324.
   PubMedGoogle Scholar
• Miyashita, T., and J. Reed 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and J. Levine 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Momand, J., and J. Zambetti 1997. Mdm-2: “big brother” of p53. J. Cell. Biochem. 64:343–352.
   PubMed Web of Science ®Google Scholar
• Oca Luna, R. M., D. S. Wagner, and J. Lozano 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206.
   PubMedGoogle Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and J. Vogelstein 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and J. Vogelstein 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860.
   PubMed Web of Science ®Google Scholar
• Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimira, A. Nakagawara, M. Obinata, and J. Ikawa 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839–843.
   PubMed Web of Science ®Google Scholar
• Piette, J., H. Neel, and J. Marechal 1997. Mdm2: keeping p53 under control. Oncogene 15:1001–1010.
   PubMed Web of Science ®Google Scholar
• Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and J. Vogelstein 1997. A model for p53-induced apoptosis. Nature 389:300–305.
   PubMed Web of Science ®Google Scholar
• Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. Lee, C. Cordon-Cardo, and J. DePinho 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723.
   PubMed Web of Science ®Google Scholar
• Prabhu, N. S., K. Somasundaram, K. Satyamoorthy, M. Herlyn, and J. El-Deiry 1998. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol. 13:5–9.
   PubMedGoogle Scholar
• Schmale, H., and J. Bamberger 1997. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363–1367.
   PubMed Web of Science ®Google Scholar
• Shikama, N., L. Lyon, and J. La Thangue 1997. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 7:230–236.
   PubMedGoogle Scholar
• Tharakan, J. 1994. Immunoaffinity purification, p. 327–340. In V. S. Malik, E. P. Lillehoj (ed.), Antibody techniques. Academic Press, Inc., New York, N.Y.
   Google Scholar
• Thut, C. J., J. L. Chen, R. Klemin, and J. Tjian 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267:100–104.
   PubMedGoogle Scholar
• Thut, C. J., J. A. Goodrich, and J. Tjian 1997. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11:1974–1986.
   PubMedGoogle Scholar
• Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and J. Sidransky 1998. A new human p53 homologue. Nat. Med. 4:747–748.
   PubMed Web of Science ®Google Scholar
• Wu, X., J. H. Bayle, D. Olson, and J. Levine 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132.
   PubMed Web of Science ®Google Scholar
• Xiao, Z., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and J. Livingston 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694–698.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and J. Beach 1993. P21 is a universal inhibitor of cyclin kinases. Nature 366:701–704.
   PubMed Web of Science ®Google Scholar
• Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and J. McKeon 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305–316.
   PubMed Web of Science ®Google Scholar
• Zeng, X. Y., A. J. Levine, and J. Lu 1998. Non-p53 p53RE binding protein, a human transcription factor functionally analogous to p53. Proc. Natl. Acad. Sci. USA 95:6681–6686.
   PubMedGoogle Scholar
• Zeng, X. Y., A. Miller, W. Yuan, R. Kwok, R. Goodman, and H. Lu. p73 and p53 activate transcription through interaction with different domains of p300/CBP. Submitted for publication.
   Google Scholar
• Zeng, X. Y., and H. Lu. Unpublished data.
   Google Scholar
• Zhang, Y., Y. Xiong, and J. Yarbrough 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734.
   PubMed Web of Science ®Google Scholar